Who is sponsoring NCT06665256?

NCT06665256 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT06665256?

Interventions in NCT06665256: Rapcabtagene autoleucel, Active Comparator Option.

What condition does NCT06665256 study?

NCT06665256 studies Idiopathic Inflammatory Myopathies.

Is NCT06665256 still recruiting?

NCT06665256 is currently recruiting now. Last updated 5 February 2026.

Last reviewed 2026-02-05 · How we verify

NCT06665256

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

Recruiting now Phase 2 Last updated 5 February 2026

What this trial tests

Phase 2 trial testing Rapcabtagene autoleucel in Idiopathic Inflammatory Myopathies in 123 participants. Currently enrolling.

Timeline

17 December 2024

Primary endpoint
17 July 2029

6 February 2033

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	123
Start date	17 December 2024
Primary completion	17 July 2029
Estimated completion	6 February 2033
Sites	55 locations across Saudi Arabia, Brazil, Netherlands, Spain, Taiwan, United Kingdom, Japan, Singapore

Drugs / interventions tested

Rapcabtagene autoleucel — full drug profile →
Active Comparator Option

Conditions studied

Idiopathic Inflammatory Myopathies — all drugs for Idiopathic Inflammatory Myopathies →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 75, any sex, with Idiopathic Inflammatory Myopathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Rapcabtagene autoleucel

Trials testing the same drug.

NCT07048197 — A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis · Phase 1, PHASE2 · recruiting
NCT06868290 — Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA · Phase 2 · recruiting

Other recruiting trials for Idiopathic Inflammatory Myopathies

Currently open trials in the same condition.

NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07295847 — A Study of AZD0120 in Autoimmune Diseases · Phase 1 · recruiting
NCT06916806 — A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants Wit · Phase 1 · recruiting
NCT07022197 — Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases · Phase 1, PHASE2 · recruiting
NCT06548607 — Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases · EARLY_PHASE1 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06665256 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 5 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06665256.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing